Insufficient CD100 shedding contributes to suppression of CD8+ T‐cell activity in non‐small cell lung cancer

• Published in: Immunology 2020-06, Vol.160 (2), p.209-219
• Main Authors: Wang, Hong‐Min, Zhang, Xiao‐Hong, Ye, Li‐Qun, Zhang, Kai, Yang, Ning‐Ning, Geng, Shen, Chen, Jing, Zhao, Shun‐Xin, Yang, Kang‐Li, Fan, Fei‐Fei
• Format: Article
• Language: English
• Subjects: Alveoli; Bronchus; CD100; CD72 antigen; CD8 antigen; CD8+ T‐cells; Cell culture; Cell membranes; Immune system; Immunoregulation; Levels; Lung cancer; Matrix metalloproteinase; Matrix metalloproteinases; Metalloproteinase; Non-small cell lung carcinoma; non‐small cell lung cancer; Original; Shedding; Small cell lung carcinoma; Tumors
• ISSN: 0019-2805; 1365-2567
• DOI: 10.1111/imm.13189

Summary CD100 is an immune semaphorin constitutively expressed on T‐cells. Matrix metalloproteinase (MMP) is an important mediator of membrane‐bound CD100 (mCD100) cleavage to generate soluble CD100 (sCD100), which has immunoregulatory activity in immune cell responses. The aim of the study was to investigate the level and role of sCD100 and mCD100 in modulating CD8+ T‐cell function in non‐small cell lung cancer (NSCLC). sCD100 and MMP‐14 levels in the serum and bronchoalveolar lavage fluid (BALF), and mCD100 expression on peripheral and lung‐resident CD8+ T‐cells were analysed in NSCLC patients. The ability to induce sCD100 and the effect of MMP‐14 on mCD100 shedding for the regulation of non‐cytolytic and cytolytic functions of CD8+ T‐cells were also analysed in direct and indirect contact co‐culture systems. NSCLC patients had lower serum sCD100 and higher mCD100 levels on CD8+ T‐cells compared with healthy controls. BALF from the tumour site also had decreased sCD100 and increased mCD100 on CD8+ T‐cells compared with the non‐tumour site. Recombinant CD100 stimulation enhanced non‐cytolytic and cytolytic functions of CD8+ T‐cells from NSCLC patients, whereas blockade of CD100 receptor CD72 attenuated CD8+ T‐cell activity. NSCLC patients had lower MMP‐14 in the serum and in BALF from the tumour site. Recombinant MMP‐14 mediated mCD100 shedding from CD8+ T‐cell membrane, and led to promotion of CD8+ T‐cell response in NSCLC patients. Overall, decreased MMP‐14 resulted in insufficient CD100 shedding, leading to suppression of peripheral and lung‐resident CD8+ T‐cell activity in NSCLC. Non‐small cell lung cancer patients had lower serum sCD100 and MMP‐14, while higher mCD100 on CD8+ T‐cells. MMP‐14‐CD100 signalling pathway enhanced the non‐cytolytic and cytolytic functions of CD8+ T‐cells through CD72. Decreased MMP‐14 mediated insufficient CD100 shedding, leading to suppression of peripheral and lung‐resident CD8+ T‐cell activity in NSCLC.